Evidence mapPaperPMID 40398671Full record

ReviewSeminars in liver disease2025

Big Data Analytics in Large Cohorts: Opportunities and Challenges for Research in Hepatology.

Helen Ye Rim Huang, Kai Markus Schneider, Carolin Schneider

Abstract readReview
In one paragraph

Review in Seminars in liver disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Helen Ye Rim HuangDepartment of Internal Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
Kai Markus SchneiderDepartment of Medicine I, Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Carolin SchneiderDepartment of Internal Medicine III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in big data analytics, precision medicine, and artificial intelligence are transforming hepatology, offering new insights into disease mechanisms, risk stratification, and therapeutic interventions. In this review, we explore how the integration of genetic studies, multi-omics data, and large-scale population cohorts has reshaped our understanding of liver disease, using steatotic liver disease as a prototype for data-driven discoveries in hepatology. We highlight the role of artificial intelligence in identifying patient subgroups, optimizing treatment strategies, and uncovering novel therapeutic targets. Furthermore, we discuss the importance of collaborative networks, open data initiatives, and implementation science in translating these findings into clinical practice. Although data-driven precision medicine holds great promise, its impact depends on structured approaches that ensure real-world adoption.

Indexed as

Big DataBiomedical ResearchGastroenterologyLiver DiseasesPrecision MedicineArtificial IntelligenceData AnalyticsHumans

Identifiers

PMID40398671
PMCPMC12422800

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.